Abstract
Psoriasis and psoriatic arthritis are debilitating inflammatory immunemediated diseases which are chronic in nature and often require lifelong attention. Traditional therapies used to combat these diseases lack sufficient long-term efficacy and are associated with a number of toxicities. Failing to adequately satisfy both patients and physicians, traditional therapies have proven insufficient and have left few options. Etanercept is a tumor necrosis factor (TNF) antagonist that reduces elevated TNF levels by competitively binding to both TNF-α and TNF-β and inhibiting the proinflammatory cascade. Providing a valuable treatment option alone, etanercept can also be effectively administered in conjunction with traditional treatments. Etanercept is self administered by subcutaneous (SC) injection, making treatment less of a burden for patients by eliminating the need for frequent office visits and laboratory testing. Etanercept is approved in the US for the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis.
Keywords: Anti-TNF, Enbrel®, Etanercept, Psoriatic arthritis, Psoriasis
Reviews on Recent Clinical Trials
Title: Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis
Volume: 1 Issue: 3
Author(s): Brian S. Fuchs and Suhail Hadi
Affiliation:
Keywords: Anti-TNF, Enbrel®, Etanercept, Psoriatic arthritis, Psoriasis
Abstract: Psoriasis and psoriatic arthritis are debilitating inflammatory immunemediated diseases which are chronic in nature and often require lifelong attention. Traditional therapies used to combat these diseases lack sufficient long-term efficacy and are associated with a number of toxicities. Failing to adequately satisfy both patients and physicians, traditional therapies have proven insufficient and have left few options. Etanercept is a tumor necrosis factor (TNF) antagonist that reduces elevated TNF levels by competitively binding to both TNF-α and TNF-β and inhibiting the proinflammatory cascade. Providing a valuable treatment option alone, etanercept can also be effectively administered in conjunction with traditional treatments. Etanercept is self administered by subcutaneous (SC) injection, making treatment less of a burden for patients by eliminating the need for frequent office visits and laboratory testing. Etanercept is approved in the US for the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis.
Export Options
About this article
Cite this article as:
Fuchs S. Brian and Hadi Suhail, Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250131
DOI https://dx.doi.org/10.2174/157488706778250131 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice
Current Pharmaceutical Design Study in Treatment of Collagen-Induced Arthritis in DBA/1 Mice Model by Genistein
Current Pharmaceutical Design Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Editorial [Hot Topic: Proteome/Protein/Peptide in Molecular Medicine (Guest Editor: John M. Luk)
Protein & Peptide Letters Effect of Alpha-1-Acid Glycoprotein Binding on Pharmacokinetics and Pharmacodynamics
Current Drug Metabolism Drug Analogs of COX-2 Selective Inhibitors Lumiracoxib and Valdecoxib Derived from in silico Search and Optimization
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review
Current Drug Targets Prostaglandins Pathway as a Possible Biological Link Between Cancer and Major Depression
Current Angiogenesis (Discontinued) Genomic Strategies in Pharmacology of Asthma and Autoimmunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry